Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 312 mg/ml (equivalent: paliperidone, qty 200 mg/ml) - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bortezomib, quantity: 3 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - - velcade, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. - velcade, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. - velcade is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. - velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bendamustine hydrochloride, quantity: 25 mg - injection, powder for - excipient ingredients: mannitol - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c). efficacy relative to first-line therapies other than chlorambucil has not been established. previously untreated indolent cd20-positive, stage iii-iv non-hodgkin?s lymphoma, in combination with rituximab. previously untreated cd20-positive, stage iii-iv mantle cell lymphoma in combination with rituximab, in patients ineligible for autologous stem cell transplantation. relapsed/refractory indolent non-hodgkin?s lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - bendamustine hydrochloride, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c). efficacy relative to first-line therapies other than chlorambucil has not been established. previously untreated indolent cd20-positive, stage iii-iv non-hodgkin?s lymphoma, in combination with rituximab. previously untreated cd20-positive, stage iii-iv mantle cell lymphoma in combination with rituximab, in patients ineligible for autologous stem cell transplantation. relapsed/refractory indolent non-hodgkin?s lymphoma.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - canagliflozin hemihydrate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - canagliflozin hemihydrate -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 156 mg (equivalent: paliperidone, qty 100 mg) - injection - excipient ingredients: dibasic sodium phosphate; water for injections; macrogol 4000; monobasic sodium phosphate monohydrate; polysorbate 20; citric acid monohydrate; sodium hydroxide - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 117 mg (equivalent: paliperidone, qty 75 mg) - injection - excipient ingredients: sodium hydroxide; polysorbate 20; macrogol 4000; water for injections; dibasic sodium phosphate; monobasic sodium phosphate monohydrate; citric acid monohydrate - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - paliperidone palmitate, quantity: 39 mg (equivalent: paliperidone, qty 25 mg) - injection - excipient ingredients: dibasic sodium phosphate; sodium hydroxide; monobasic sodium phosphate monohydrate; citric acid monohydrate; polysorbate 20; water for injections; macrogol 4000 - invega sustenna is indicated for the acute and maintenance treatment of schizophrenia in adults.